Ultragenyx Plans Five Clinical Trials For 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
The rare disease biotech is confident it can move all of its programs forward and has no interest in selling its commercialization rights to a Big Pharma partner.
You may also be interested in...
Financings Of The Fortnight Not Seeing A Trickle-Down Investment Effect From Last Year’s IPOs
The 2013 life sciences IPO boom does not necessarily augur more of the same for those biotechs now lining up to go public. Plus financing news from Juno Therapeutics, GlycoMimetics, Ultragenyx and Alkermes.
Biotech IPOs Are Back: First Four For Fall Hit The Road
After a slow August and early September, Wall Street is preparing for four biotech IPOs. Biotech IPOs have been on fire, outperforming even the vigorous biotech indices. But the question remains – can public investors get too much of a good thing?
Ultragenyx Takes On Rare Childhood Disease With In-licensing Deal
Rare disease company Ultragenyx has in-licensed the North American rights to a treatment for fatty-acid oxidation disorder, adding its third clinical-stage drug to its ultra-rare disease pipeline.